- Home
- ACET vs SIEB Comparison
ACET vs SIEB Comparison
Compare ACET & SIEB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ACET
- SIEB
- Stock Information
- Founded
- ACET 1947
- SIEB 1886
- Country
- ACET United States
- SIEB United States
- Employees
- ACET N/A
- SIEB N/A
- Industry
- ACET Biotechnology: Pharmaceutical Preparations
- SIEB Investment Bankers/Brokers/Service
- Sector
- ACET Health Care
- SIEB Finance
- Exchange
- ACET Nasdaq
- SIEB Nasdaq
- Market Cap
- ACET 111.9M
- SIEB 115.6M
- IPO Year
- ACET N/A
- SIEB N/A
- Fundamental
- Price
- ACET $0.58
- SIEB $3.09
- Analyst Decision
- ACET Buy
- SIEB
- Analyst Count
- ACET 4
- SIEB 0
- Target Price
- ACET $8.50
- SIEB N/A
- AVG Volume (30 Days)
- ACET 1.8M
- SIEB 19.3K
- Earning Date
- ACET 11-05-2025
- SIEB 11-12-2025
- Dividend Yield
- ACET N/A
- SIEB N/A
- EPS Growth
- ACET N/A
- SIEB N/A
- EPS
- ACET N/A
- SIEB 0.18
- Revenue
- ACET N/A
- SIEB $90,289,000.00
- Revenue This Year
- ACET N/A
- SIEB N/A
- Revenue Next Year
- ACET N/A
- SIEB N/A
- P/E Ratio
- ACET N/A
- SIEB $17.27
- Revenue Growth
- ACET N/A
- SIEB 8.32
- 52 Week Low
- ACET $0.45
- SIEB $2.08
- 52 Week High
- ACET $1.19
- SIEB $5.77
- Technical
- Relative Strength Index (RSI)
- ACET 36.18
- SIEB 62.09
- Support Level
- ACET $0.57
- SIEB $2.83
- Resistance Level
- ACET $0.67
- SIEB $3.16
- Average True Range (ATR)
- ACET 0.06
- SIEB 0.18
- MACD
- ACET 0.00
- SIEB 0.05
- Stochastic Oscillator
- ACET 26.97
- SIEB 99.30
About ACET Adicet Bio Inc.
Adicet Bio Inc is a clinical-stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for cancer and other diseases. Its product candidate, ADI-001, a first-in-class allogeneic gamma delta T cell therapy expressing a CAR targeting CD20, is being developed for the potential treatment of autoimmune diseases and relapsed or refractory aggressive B cell non-Hodgkin's lymphoma. Their pipeline also includes its preclinical candidate, ADI-270, an armored gamma delta CAR T cell product candidate targeting renal cell carcinoma, with potential for other CD70+ solid tumor and hematological malignancies indications.
About SIEB Siebert Financial Corp.
Siebert Financial Corp is a diversified financial services firm and provides a full range of brokerage and financial advisory services including securities brokerage, investment advisory and insurance offerings, and corporate stock plan administration solutions. The firm mainly provides online and traditional brokerage and related services to retail investors and also acts as an investment advisor for its subsidiary. The company operates in the securities brokerage and asset management industry. It also engages in Insurance services, Robo-advisory technology, and Prime brokerage business through its subsidiaries.